Company: GANX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001558370-25-005829
Chunk: 46

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 46
---
ance payments and benefits is subject to Mr. Mack signing (and not revoking) a release of claims within the time period stated therein, but in no event later than sixty days after the termination.

In addition, the Mack CEO Amendment provides that Mr. Mack is eligible for equity incentive grants as determined by the Board in its sole discretion from time to time. Mr. Mack is also eligible to participate in our employee benefit plans, as may be maintained by us from time to time, on the same terms as other similarly situated employees of the Company.

Chief Financial Officer (April 2024 to January 2025)

In connection with his appointment as our Chief Financial Officer, we entered into an employment agreement with Mr. Mack, effective as of April 8, 2024 (the “Mack CFO Employment Agreement”) whereby Mr. Mack was entitled to receive an annual base salary of $370,000 and was eligible to receive, as determined by the Board in its sole discretion, an annual incentive cash bonus that was initially set at a target of 35% of his annual base salary.

As a material inducement to Mr. Mack to enter into the Mack CFO Employment Agreement, the Board also approved the grant to Mr. Mack of an inducement equity award consisting of an option to purchase up to 200,000 shares of our common stock at an exercise price of $3.56 per share pursuant to our 2021 Inducement Plan, vesting over a four year period with 25% vesting on the first anniversary thereof and the balance vesting in equal monthly installments over the remainder of the vesting period.

In the event of termination of Mr. Mack’s employment as Chief Financial Officer by us without cause, by Mr. Mack for good reason or Mr. Mack’s employment terminated upon his death or disability, in all cases subject to Mr. Mack entering into and not revoking a separation agreement in a form acceptable to us, he would have been eligible to receive cash severance equal to six (6) months of base salary. In addition, if Mr. Mack timely elected to receive continued coverage under the Company’s group health care plan pursuant to COBRA or applicable state continuation coverage laws, then he would have been eligible to receive payment of the employer portion of his COBRA premiums for the six (6) month period after the termination of employment occurred.

If such termination occurred on the date of a change of control or within twelve (12) months thereafter, then as additional components of severance